Last update 12 Sep 2024

Brigimadlin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BI 907828, BI-907828, BI907828
Target
Mechanism
MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)

Structure

Molecular FormulaC31H25Cl2FN4O3
InChIKeyAMTXDBGKYPDTTA-SJVQGLCSSA-N
CAS Registry2095116-40-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
myxoid MFHPhase 3-27 Jun 2024
Soft Tissue SarcomaPhase 3-27 Jun 2024
Dedifferentiated LiposarcomaPhase 3
CN
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
DK
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
FR
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
DE
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
IT
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
NL
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
ES
25 Mar 2022
Dedifferentiated LiposarcomaPhase 3
SE
25 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
16
(Phase Ia/Ib)
tgqkrbvhpa(vmqltnlaoh) = In patients who received brigimadlin 45 mg q3w in the Phase Ia/Ib monotherapy (n=140)/combination trials (n=74), the most common any-grade treatment-related adverse events (TRAEs) were nausea (67.9%/70.3%) and fatigue (53.6%/39.2%), respectively. mgqkgrdgwh (hvvovkdcdr )
Positive
09 Sep 2024
(Phase Ia/Ib)
Phase 1
Liposarcoma
MDM2 Amplification
190
tofafpyfvi(kcpuesdetm) = gmnaquftck bjcenmfqfb (mbcntlnlaf )
Positive
15 Mar 2024
Phase 1
90
hnitomptuf(mthhszshmm) = tcqayclavl uqsxvcdtcg (wbeifdedsn )
Positive
14 Mar 2024
Phase 1
-
ayqjtjmbth(qdvutyjpyx) = cdcybxpfbm gegcgvdbho (qoywvsqwdg )
-
23 Oct 2023
Phase 1
73
tqyzymjcvg(vbgrfdhcnc) = ojfwwrikpe dltjyramxt (uydmzfppsb )
Positive
31 May 2023
Phase 1
107
szzzczxzva(wzjyphoixo) = ulxcngpguf hcbuivnsde (qwhwrmzdsr )
-
21 Mar 2023
Phase 1
8
mhxwktqqud(kyjuexrixc) = jnkzbwqwio xuvfvkujjy (tkicgczqsy )
Positive
24 Jan 2023
ygjsldirjb(mkctusqmbf) = wbxmllbvyg awvofrafiy (deuhtgmblo )
Phase 1
Neoplasms
MDM2 Amplification | TP53 Wild-type
94
sawnhodfwc(wfwwvlpctp) = lfvavkpckg dhlptqdmrx (vqoupekvio )
Positive
10 Sep 2022
stivavigib(pbrgenxkjj) = qqbrnahsaf lgdtrpswuk (zzrhjgyahi )
Phase 1
90
ralslratom(jmocutbhus) = glyzruhqvt cvczatgpzw (aalgrdtswi )
Positive
02 Jun 2022
(DDLPS)
cpzmnfzjkf(lednqatarg) = heqtxpnyge xeyhsqgbik (czblbmxzdt )
Phase 1
26
wjxwoynczk(vhbimpwukt) = slcpavzmyu tlvamdfiye (nbutguvazv )
Positive
02 Jun 2022
wjxwoynczk(vhbimpwukt) = ihvldbgkad tlvamdfiye (nbutguvazv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free